Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis (Q38127463)

29 August 2017

Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis (English)

1 reference

29 August 2017

0 references

Martin Stangel

1

1 reference

PubMed ID

23927662

29 August 2017

Ralf A Linker

series ordinal

2

1 reference

PubMed ID

23927662

29 August 2017

language of work or name

English

0 references

publication date

1 July 2013

1 reference

Expert Review of Clinical Pharmacology

29 August 2017

1 reference

29 August 2017

6

1 reference

29 August 2017

4

1 reference

29 August 2017

355-362

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

29 August 2017

1 reference

Multiple sclerosis: an immune or neurodegenerative disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Pharmacokinetics of oral fumarates in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.811826

10.1586/17512433.2013.811826

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23927662